4-(3-chloro-4-methoxybenzylamino)-2-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-N-((trans)-4-methoxycyclohexyl)pyrimidine-5-carboxamide

ID: ALA3354285

Chembl Id: CHEMBL3354285

PubChem CID: 118720076

Max Phase: Preclinical

Molecular Formula: C25H34ClN5O4

Molecular Weight: 504.03

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)N[C@H]2CC[C@H](OC)CC2)cc1Cl

Standard InChI:  InChI=1S/C25H34ClN5O4/c1-34-19-8-6-17(7-9-19)29-24(33)20-14-28-25(31-11-3-4-18(31)15-32)30-23(20)27-13-16-5-10-22(35-2)21(26)12-16/h5,10,12,14,17-19,32H,3-4,6-9,11,13,15H2,1-2H3,(H,29,33)(H,27,28,30)/t17-,18-,19-/m0/s1

Standard InChI Key:  UBWIPQLTJURLSV-FHWLQOOXSA-N

Alternative Forms

  1. Parent:

    ALA3354285

    ---

Associated Targets(non-human)

PDE5A Phosphodiesterase 5A (190 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Corpus cavernosum (62 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 504.03Molecular Weight (Monoisotopic): 503.2299AlogP: 3.40#Rotatable Bonds: 9
Polar Surface Area: 108.84Molecular Species: NEUTRALHBA: 8HBD: 3
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 5.55CX LogP: 3.63CX LogD: 3.62
Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.48Np Likeness Score: -1.03

References

1. Sakamoto T, Koga Y, Hikota M, Matsuki K, Murakami M, Kikkawa K, Fujishige K, Kotera J, Omori K, Morimoto H, Yamada K..  (2014)  The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.,  24  (23): [PMID:25455484] [10.1016/j.bmcl.2014.10.008]

Source